Biopharmaceutical company BerGenBio ASA (OSE:BGBIO) announced on Tuesday a collaboration with precision medicine company Tempus AI Inc (NASDAQ:TEM) to accelerate the development of its selective AXL kinase inhibitor, bemcentinib, in first-line non-small cell lung cancer (NSCLC) patients with STK11 mutations.
This partnership will provide BerGenBio access to Tempus' real-world clinical and molecular data to enhance its ongoing Phase 1b/2a BGBC016 trial. Tempus' AI-enabled platform will provide insights into the genomic landscape and treatment responses of NSCLC patients with STK11 mutations.
Upon completion of the BGBC016 study, the companies plan to present insights derived from the resulting data to regulatory agencies.
Biosergen completes first successful BSG005 treatment in invasive fungal trial
Merck discontinues Phase 3 trials KEYNOTE-867 and KEYNOTE-630
EydisBio receives USD2.6m SBIR grant from NIH's National Heart, Lung, and Blood Institute
Hyundai Bioscience to conduct Phase 3 trial for high-risk COVID-19 patients
GSK's Nucala approved in Japan for chronic rhinosinusitis with nasal polyps
RedHill Biopharma's Opaganib receives US FDA orphan-drug designation
Getinge to acquire Paragonix Technologies
Bridge Biotherapeutics and HitGen sign joint research agreement
Johnson & Johnson receives FDA approval for lung cancer treatment
GSK secures Breakthrough Therapy Designation for lung cancer drug
Phanes Therapeutics' PT217 receives US FDA orphan drug designation
Akeso's ivonescimab supplemental New Drug Application receives Chinese regulator's priority review
Pfizer reports positive results for ABRYSVO RSV vaccine in immunocompromised adults